Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections

International Journal of Infectious Diseases

Volumn 40, Issue , 2015, Pages 71-74

  Zumla, Alimuddin ^a,b   Azhar, Esam I ^b   Arabi, Yaseen ^c   Alotaibi, Badriah ^d   Rao, Martin ^e   McCloskey, Brian ^f   Petersen, Eskild ^g   Maeurer, Markus ^e  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d MINISTRY OF HEALTH   (Saudi Arabia)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW STROMA CELL; CORONAVIRIDAE INFECTION; DRUG REPOSITIONING; HUMAN; IMMUNE RESPONSE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; PATHOGENESIS; TREATMENT OUTCOME; ADULT; CORONAVIRUS INFECTIONS; CROSS INFECTION; EPIDEMIC; IMMUNOCOMPROMISED PATIENT; LUNG; SAUDI ARABIA; SOUTH KOREA;

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; REPUBLIC OF KOREA; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 84966263977     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.09.005     Document Type: Editorial

References (59)

1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en [accessed on 16 August 2015].
2. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews 2015;28:465-522.
3. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al., SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25.
4. Bui C, Bethmont A, Chughtai AA, Gardner L, Sarkar S, Hassan S, et al. A Systematic Review of the Comparative Epidemiology of Avian and Human Influenza A H5N1 and H7N9 - Lessons and Unanswered Questions. Transbound Emerg Dis 2015 Jan 29. http://dx.doi.org/10.1111/tbed.12327 [Epub ahead of print].
5. Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broadspectrum antiviral therapeutics. PloS one 2011;6(7):e22572.
6. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
7. http://www.who.int/emergencies/mers-cov/en/ [accessed 6 September, 2015].
8. van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol 2015 Jan;235(2):175-84. http:// dx.doi.org/10.1002/path.4458. Review.
9. World Health Organization. Middle East Respiratory Syndrome coronavirus (MERS-CoV) - Saudi Arabia. http://www.who.int/csr/don/12-august-2015- mers-saudi-arabia/en [accessed on 6 September2015].
10. WHO MERS-CoV Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS currents 2013;5.
11. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. The New England journal of medicine 2013;369(5):407-16.
12. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet infectious diseases 2013;13(9):752-61.
13. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Intl J Infect Dis 2014;29:301-6.
14. Lee SS, Wong NS. Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea. Int J Infect Dis 2015;38:65-7.
15. Hui DS, Perlman S, Zumla A. Spread of MERS to South Korea and China. The lancet Respiratory medicine 2015;3:509-10.
16. Petersen E, Hui DS, Perlman S, Zumla A. Middle East Respiratory Syndromeadvancing the public health and research agenda on MERS- lessons from the South Korea outbreak. Int J Infect Dis 2015;36:54-5.
17. Mizumoto K, Saitoh M, Chowell G, Miyamatsu Y, Nishiura H. Estimating the risk of Middle East respiratory syndrome (MERS) death during the course of the outbreak in the Republic of Korea, 2015. Int J Infect Dis 2015;39:7-9.
18. WHO/MERS/Clinical/15.1.http://apps.who.int/iris/bitstream/10665/178529/1/ WHO_MERS_Clinical_15.1_eng.pdf. Accessed 23rd August 2015.
19. WHO Report: Clinical management of severe acute respiratory infections when MERS coronavirus is suspected: What to do and what not to do Interim guidance 2015WHO/MERS/Clinical/15.
20. Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Current opinion in pulmonary medicine 2014;20(3): 233-41.
21. WHO Report: Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. Interim guidance. Updated 2 July 2015.
22. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Intl J Infect Dis 2014;20:42-6.
23. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. The Journal of infection 2013;67(6):606-16.
24. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014;14:1090-5.
25. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, et al. IFNalpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. Journal Antimicrob Chemother 2015;70:2129-32.
26. Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. International Journal of Antimicrobial Agents 2014.
27. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon- alpha2b and ribavirin. Scientific reports 2013;3:1686.
28. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir Ther 2015;20:87-91.
29. Lurie N, Maniolo T, Patterson AP, Collins F, Frieden T. Research as a part of the public health emergency response. N Engl J Med 2013;368:1251-5.
30. Hui DS, Zumla A. Advancing priority research on the Middle East respiratory syndrome coronavirus. The Journal of infectious diseases 2014;209(2): 173-6.
31. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. The New England Journal of Medicine 2013;368:2487-94.
32. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015 Jun 3 [Epub ahead of print] Review.
33. Smits SL, van den Brand JM, de Lang A, Leijten LM, van Ijcken WF, van Amerongen G, et al. Distinct severe acute respiratory syndrome coronavirusinduced acute lung injury pathways in two different nonhuman primate species. J Virol 2011;85:4234-45.
34. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Annals of internal medicine 2014;160(6): 389-97.
35. Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF, et al. Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 2014;23:63-8.
36. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer Journal 2014;20:119-22.
37. Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfiq JA, et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis 2014;14:1136-49.
38. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agent Chemother 2015;59:1088-99.
39. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4- mediated entry of the Middle East respiratory syndrome coronavirus. J Virology 2014;88:1834-8.
40. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014;58:4885-93.
41. Zumla A, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov 2015 Aug;14(8):511-2. http://dx.doi.org/10.1038/nrd4696. Epub 2015 Jul 17.
42. Zumla A, Maeurer M, Host-Directed Therapies Network (HDT-NET) Consortium, Host-Directed Therapies Network HDT-NET Consortium. Host-Directed Therapies for tackling Multi-Drug Resistant TB - learning from the Pasteur-Bechamp debates. Clin Infect Dis 2015 Jul 28. pii: civ631. [Epub ahead of print].
43. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agent Chemother 2014;58: 4885-93.
44. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417-35.
45. Singla S, Jacobson JR. Statins as a novel therapeutic strategy in acute lung injury. Pulm Circ 2012;2:397-406.
46. Dinarello C. Anti-inflammatory agents: present and future. Cell 2010;140: 935-50.
47. Henter JI, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmer K. Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010;376:2116.
48. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010;70:4850-8.
49. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, et al. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008;178:168-79.
50. Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol 2015;35:1071-9.
51. Goktolga U, Cavkaytar S, Altinbas SK, Tapisiz OL, Tapisiz A, Erdem O. Effect of the non-specific matrix metalloproteinase inhibitor Doxycycline on endometriotic implants in an experimental rat model. Exp Ther Med 2015;9:1813-8.
52. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agent Chemother 2014;58:4875-84.
53. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24-32.
54. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 2015 Aug 11. http://dx.doi.org/10.7326/M15-0715.
55. Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 2005;28:517-24.
56. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004;114:1059-69.
57. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20:Error: FPage (119) is higher than LPage (122)!.
58. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014;2(2):108-22. http://dx.doi.org/10.1016/ S2213-2600(13)70234-0 [Epub 2014 Jan 9].
59. Zhang Z, Fu J, Xu X, Wang S, Xu R, Zhao M, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1- infected patients. AIDS 2013;27(8):1283-93. http://dx.doi.org/10.1097/QAD.0- b013e32835fab77.